SCHEMBL2852441

SCHEMBL2852441

Cc1cc(C)n(C2CCNCC2)n1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.46
PKM P14618 1/20 0.46
ALOX15 P16050 1/20 0.46
KMT2A Q03164 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
NSD3 Q9BZ95 1/20 0.44
KDM5A P29375 1/20 0.42
CHRNB2 P17787 3/20 0.41
CHRNA4 P43681 3/20 0.41
BRD4 O60885 8/20 0.39
BRD2 P25440 1/20 0.38
BRD3 Q15059 1/20 0.38
BRDT Q58F21 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
GABRA1 P14867 1/20 0.36
GABRB2 P47870 1/20 0.36
KDM1A O60341 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15942127 0.89 KDM5A (0.38) MEN1ALDH1A1MAPTPKMALOX15
SCHEMBL15935405 0.86 SMN1; SMN2 (0.41) MEN1ALDH1A1KMT2AKDM5ASMN1; SMN2
SCHEMBL23748795 0.82 KDM4E (0.46) ALDH1A1KDM5ASMN1; SMN2
SCHEMBL23546398 0.82 MEN1 (0.44) MEN1ALDH1A1MAPTPKMALOX15
SCHEMBL16339809 0.81 KDM5A (0.41) MEN1ALDH1A1ALOX15KMT2AKDM5A
SCHEMBL31462462 0.81 ALDH1A1 (0.49) ALDH1A1KDM5ASMN1; SMN2
SCHEMBL3364096 0.81 ALDH1A1 (0.49) ALDH1A1KDM5ASMN1; SMN2
SCHEMBL4288446 0.80 NSD3 (0.44) MEN1ALDH1A1MAPTPKMALOX15
SCHEMBL30022464 0.80 F10 (0.42) KDM5ASMN1; SMN2
SCHEMBL28720539 0.79 SMN1; SMN2 (0.38) MEN1ALDH1A1ALOX15KMT2AKDM5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790725-B2 Thiazolidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-07 US disclosed
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2007-11-08 US disclosed
CN-100341862-C Thiazolidine derivative and medicinal use thereof MITSUBISHI PHARMA CORP (JP) 2007-10-10 CN disclosed
CN-1606549-A Thiazolidine derivative and medical application thereof MITSUBISHI PHARMA CORP (JP) 2005-04-13 CN disclosed
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-12-23 US disclosed
EP-1426366-A1 THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF DPP4, DPP7, DPP3 MEN1 3295/4885ALDH1A1 148/4885MAPT 3150/4885
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof DPP4, DPP7, DPP3 MEN1 2196/4885ALDH1A1 31/4885MAPT 3522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.